Entinostat (Syndax/GSK) enetrs Phase I/II trial for Breast Cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/II study combining entinostat, a benzamide histone deacetylase inhibitor, from Syndax Pharma with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic Breast Cancer previously treated with trastuzumab (Herceptin). The study sponsored by MD Anderson Cancer Center is being conducted in collaboration with the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis and GSK. Preclinical data has demonstrated that entinostat, a novel, selective histone deacetylase inhibitor can overcome acquired resistance to HER-2 targeted therapies when combined with lapatinib.